D. Descamps

发表

Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients.

Y. Yazdanpanah, N. Néant, C. Solas, 2019, The Journal of antimicrobial chemotherapy.

HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms.

B. J. Betts, R. Shafer, F. Brun-Vézinet, 2003, Journal of acquired immune deficiency syndromes.

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

Y. Yazdanpanah, B. Bosch, M. Koopmans, 2020, Emerging infectious diseases.

Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism.

V. Calvez, B. Masquelier, J. Izopet, 2011, The Journal of antimicrobial chemotherapy.

Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021)

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2005, Journal of Virology.

Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy

Jacques Izopet, Diane Descamps, F. Brun-Vézinet, 2001, Journal of Virology.

Usefulness of multiplex PCR methods and respiratory viruses’ distribution in children below 15 years old according to age, seasons and clinical units in France: A 3 years retrospective study

C. Charpentier, L. Mandelbrot, D. Descamps, 2017, PloS one.

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

C. Katlama, C. Fagard, Y. Yazdanpanah, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

V. Calvez, C. Charpentier, J. Pawlotsky, 2015, PloS one.

In Vitro Phenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors

C. Charpentier, F. Brun-Vézinet, G. Peytavin, 2011, Antimicrobial Agents and Chemotherapy.

Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study

C. Charpentier, B. Masquelier, J. Izopet, 2010, Antimicrobial Agents and Chemotherapy.

Evaluation of an Upgraded Version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test for HIV-1 Load Quantification

F. Brun-Vézinet, C. Rouzioux, D. Descamps, 2010, Journal of Clinical Microbiology.

Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV‐1 Non‐nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine

V. Calvez, F. Ceccherini‐Silberstein, B. Masquelier, 2011, ChemMedChem.

High frequency of selection of K65R and Q151M mutations in HIV‐2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen

F. Brun-Vézinet, D. Descamps, G. Chêne, 2004, Journal of medical virology.

Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.

D. Descamps, J. Parienti, B. Larouze, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of Zidovudine Resistance Mutations on Virologic Response to Treatment With Zidovudine or Stavudine, Each in Combination With Lamivudine and Indinavir

F. Brun-Vézinet, J. Izopet, G. Peytavin, 2002, Journal of acquired immune deficiency syndromes.

Hiv-2 molecular epidemiology.

C. Charpentier, D. Descamps, S. Matheron, 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2008, Antimicrobial Agents and Chemotherapy.

HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial

Steve Kaye, Francoise Brun-Vezinet, Rob Schuurman, 1997, The Lancet.

HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.

D. Jeffries, A. Breckenridge, F. Brun-Vézinet, 1999, AIDS.

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2020, The Journal of antimicrobial chemotherapy.

Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2018, The Journal of antimicrobial chemotherapy.

HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.

C. Rouzioux, P. Frange, G. Peytavin, 2016, The lancet. HIV.

Metabolic syndrome and endocrine status in HIV-infected transwomen

Y. Yazdanpanah, J. Guibourdenche, G. Peytavin, 2019, AIDS.

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

V. Calvez, C. Charpentier, O. Delelis, 2017, mBio.

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2011, The Journal of antimicrobial chemotherapy.

High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2015, AIDS.

Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.

H. Mal, M. Lê, G. Peytavin, 2013, The Journal of antimicrobial chemotherapy.

Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment‐Naive HIV‐Infected Patients

X. Panhard, B. Vrijens, R. Savic, 2012, Clinical pharmacology and therapeutics.

Improved Sensitivity of Human Immunodeficiency Virus Type 2 Subtype B Plasma Viral Load Assay

F. Brun-Vézinet, D. Descamps, G. Chêne, 2005, Journal of Clinical Microbiology.

Benefits of resistance testing

F. Brun-Vézinet, D. Descamps, 2006 .

Evolution of Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Mutations in Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) in HIV-1-Infected Patients Switched to Antiretroviral Therapy without NNRTIs

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2004, Antimicrobial Agents and Chemotherapy.

OP-JANM210249 20..27

J. Lucet, E. Casalino, F. Lescure, 2021 .

The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients

V. Calvez, C. Charpentier, D. Boutolleau, 2021, Journal of Infection.

Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries

V. Calvez, F. Brun-Vézinet, M. Peeters, 2018, The Journal of antimicrobial chemotherapy.

Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients.

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2008, AIDS.

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Mark S. Anderson, Chun Jimmie Ye, Gabriela K. Fragiadakis, 2022, Science immunology.

Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.

Y. Yazdanpanah, A. Desnoyer, P. Muret, 2016, Journal of hepatology.

Conventional Dendritic Cells and Slan+ Monocytes During HIV-2 Infection

C. Charpentier, F. Brun-Vézinet, A. Samri, 2020, Frontiers in Immunology.

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.

A. Wensing, H. Günthard, P. Reiss, 2016, The Journal of antimicrobial chemotherapy.

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.

C. Charpentier, F. Brun-Vézinet, Y. Yazdanpanah, 2014, The Journal of antimicrobial chemotherapy.

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

V. Calvez, C. Charpentier, B. Masquelier, 2013, The Journal of antimicrobial chemotherapy.

Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.

D. Costagliola, D. Descamps, V. Joly, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-term neuro-functional disability in adult patients with community-acquired bacterial meningitis

A. Péchinot, G. Béraud, G. Barnaud, 2022, Infection.

Contribution of rapid lateral flow assays from capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a pilot study in a university hospital, Paris, France

C. Charpentier, D. Descamps, M. Aubier, 2021, Diagnostic Microbiology and Infectious Disease.

SARS-CoV-2 specific antibody responses in COVID-19 patients

Y. Yazdanpanah, B. Bosch, M. Koopmans, 2020, medRxiv.

The value of open-source clinical science in pandemic response: lessons from ISARIC

Siti Zubaidah Othman, Karl Erik Müller, Jose M. Mandei, 2021, The Lancet Infectious Diseases.

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2

C. Charpentier, Y. Yazdanpanah, D. Descamps, 2021, Viruses.

HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution

C. Charpentier, F. Collin, D. Descamps, 2021, Virus evolution.

Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces

Tatiana F. Vieira, C. Charpentier, O. Delelis, 2022, Antimicrobial agents and chemotherapy.

Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2012, The Journal of infectious diseases.

HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients

C. Charpentier, F. Brun-Vézinet, R. Tubiana, 2014, AIDS.

Long-Lasting Persistence of Integrase Resistance Mutations in HIV-2-Infected Patients after Raltegravir Withdrawal

C. Charpentier, F. Brun-Vézinet, O. Delelis, 2011, Antiviral therapy.

Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives

Inserm, Shana M Augustin, C. Charpentier, 2020, Clinical Microbiology and Infection.

Analysis of the HIV-2 protease’s adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet

A. Camproux, Leslie Regad, D. Descamps, 2018, Scientific Reports.

Arterial Thrombotic Events in Adult Inpatients With COVID-19

Q. Pellenc, Y. Castier, Y. Yazdanpanah, 2020, Mayo Clinic Proceedings.

Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016

C. Charpentier, Y. Yazdanpanah, J. Timsit, 2017, PloS one.

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

C. A. Shaw, Eglantine Ferrand Devouge, Su Hwan Lee, 2022, Critical Care.

Relationship between serotypes, disease characteristics and 30-day mortality in adults with invasive pneumococcal disease

F. Vandenesch, A. Péchinot, G. Béraud, 2021, Infection.

New insights in COVID-19–associated chilblains: A comparative study with chilblain lupus erythematosus

C. Charpentier, A. Couvelard, D. Descamps, 2020, Journal of the American Academy of Dermatology.

Genetic diversity and HIV detection by polymerase chain reaction

F. Brun-Vézinet, D. Descamps, S. Saragosti, 1995, The Lancet.

Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients

J. Timsit, L. Bouadma, M. Lê, 2020, The Journal of antimicrobial chemotherapy.

No association between human herpesvirus or herpesvirus saimiri and idiopathic pulmonary fibrosis

C. Charpentier, A. Cazes, B. Crestani, 2020, ERJ Open Research.

Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine

C. Charpentier, Y. Yazdanpanah, J. Timsit, 2021, Journal of Infection.

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients

C. Katlama, C. Fagard, Y. Yazdanpanah, 2010, AIDS.

Phylodynamics of SARS-CoV-2 transmissions in France, Europe and the world during 2020

V. Calvez, C. Charpentier, D. Descamps, 2022, medRxiv.

Tropism distribution among antiretroviral-naive HIV-2-infected patients

C. Charpentier, F. Brun-Vézinet, C. Fagard, 2015, AIDS.

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates

C. Charpentier, F. Brun-Vézinet, G. Peytavin, 2015, PloS one.

Impact of respiratory viruses in hospital-acquired pneumonia in the intensive care unit: A single-center retrospective study

Y. Yazdanpanah, J. Timsit, L. Bouadma, 2017, Journal of Clinical Virology.

No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohort

F. Brun-Vézinet, D. Descamps, G. Chêne, 2006, AIDS.

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing

V. Calvez, C. Charpentier, C. Katlama, 2018, The Journal of antimicrobial chemotherapy.

Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen.

C. Charpentier, F. Raffi, D. Descamps, 2014, The Journal of antimicrobial chemotherapy.

HIV2EU: supporting standardized HIV‐2 drug resistance interpretation in Europe

C. Charpentier, R. Kaiser, F. Brun-Vézinet, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Selection of K65R Mutation in HIV-2-Infected Patients Receiving Tenofovir-Containing Regimen

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2004, Antiviral therapy.

Human Immunodeficiency Virus Type 1 (HIV-1) Plasma Load Discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assays

F. Brun-Vézinet, D. Descamps, B. Roquebert, 2007, Journal of Clinical Microbiology.

HIV-1 subtypes and plasma RNA quantification.

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1999, AIDS.

HIV-1 diagnosis with unquantifiable viraemia: don’t be naive, look for antiretroviral drugs

V. Calvez, C. Charpentier, R. Tubiana, 2017, Journal of Antimicrobial Chemotherapy.

Combined Bacterial Meningitis and Infective Endocarditis: When Should We Search for the Other When Either One is Diagnosed?

B. Iung, A. Péchinot, T. Doco‐Lecompte, 2022, Infectious Diseases and Therapy.

Piloting a surveillance system for HIV drug resistance in the European Union

M. Poljak, A. Pharris, A. Amato-Gauci, 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Adherence Profiles and Therapeutic Responses of Treatment-Naive HIV-Infected Patients Starting Boosted Atazanavir-Based Therapy in the ANRS 134-COPHAR 3 Trial

X. Panhard, B. Vrijens, D. Descamps, 2013, Antimicrobial Agents and Chemotherapy.

One-Year Sequelae and Quality of Life in Adults with Meningococcal Meningitis: Lessons from the COMBAT Multicentre Prospective Study

F. Vandenesch, A. Péchinot, G. Béraud, 2022, Advances in Therapy.

Performance evaluation of the QIAstat-Dx® Respiratory SARS-CoV-2 Panel

D. Manissero, Josep Pareja, D. Descamps, 2021, International Journal of Infectious Diseases.

Evaluation of the RealStar® SARS-CoV-2 RT-PCR kit RUO performances and limit of detection

D. Descamps, Q. Le Hingrat, N. Houhou-Fidouh, 2020, Journal of Clinical Virology.

Oropharyngeal and intestinal concentrations of opportunistic pathogens are independently associated with death of SARS-CoV-2 critically ill adults

C. Charpentier, J. Timsit, J. Hulot, 2022, Critical Care.

Exploration of the effects of sequence variations between HIV-1 and HIV-2 proteases on their three-dimensional structures

A. Camproux, Leslie Regad, D. Descamps, 2019, Journal of biomolecular structure & dynamics.

Characterizing the structural variability of HIV-2 protease upon the binding of diverse ligands using a structural alphabet approach

A. Camproux, Leslie Regad, D. Descamps, 2019, Journal of biomolecular structure & dynamics.

Short communication: Prevalence of HIV-1 transmitted drug resistance in Liberia.

C. Charpentier, Y. Yazdanpanah, G. Peytavin, 2014, AIDS research and human retroviruses.

Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.

C. Charpentier, F. Brun-Vézinet, J. Capeau, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Alpha (B.1.1.7) and Delta (B.1.617.2 – AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage

C. Charpentier, Y. Yazdanpanah, J. Timsit, 2021, Journal of Infection.

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma

V. Calvez, C. Delaugerre, S. Yerly, 2017, The Journal of antimicrobial chemotherapy.

Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.

V. Calvez, C. Charpentier, C. Katlama, 2016, The Journal of antimicrobial chemotherapy.

Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.

V. Calvez, C. Charpentier, C. Katlama, 2015, AIDS research and human retroviruses.

Impact of Adding Enfuvirtide to the Predictive Value of the Darunavir Genotypic Resistance Score

C. Charpentier, F. Brun-Vézinet, C. Katlama, 2011, Journal of acquired immune deficiency syndromes.

Predictors and Outcomes of HIV-Infected Antiretroviral-Naive Patients With Discordant Responses to Combination Antiretroviral Treatment in Asian and Australian Populations : Results From APHOD

V. Calvez, G. Peytavin, D. Descamps, 2011 .

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.

V. Calvez, C. Delaugerre, S. Yerly, 2015, The Journal of antimicrobial chemotherapy.

Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19

J. Timsit, H. Mal, M. Lê, 2020, Antimicrobial Agents and Chemotherapy.

Methicillin-resistant Staphylococcus aureus with the novel mecC gene variant isolated from a cat suffering from chronic conjunctivitis

S. Yerly, H. Fleury, D. Descamps, 2013 .

On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases.

D. Descamps, O. Launay, V. Joly, 2002, Journal of acquired immune deficiency syndromes.

HIV‐1 non‐group M phenotypic susceptibility to integrase strand transfer inhibitors

C. Charpentier, D. Descamps, J. Plantier, 2017, The Journal of antimicrobial chemotherapy.

Undetectable HIV‐1 RNA load with the Cobas TaqMan v1.0 in a patient diagnosed at the time of primary HIV‐1 infection

C. Rouzioux, L. Meyer, D. Descamps, 2010, Journal of medical virology.

Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases

D. Descamps, T. Papo, K. Sacré, 2022, The Lancet Rheumatology.

Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients

Siti Zubaidah Othman, Eyvind W. Axelsen, C. A. Shaw, 2022, Influenza and other respiratory viruses.

The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients

V. Calvez, C. Charpentier, S. Burrel, 2021, Journal of Infection.

Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.

C. Charpentier, Y. Yazdanpanah, D. Descamps, 2015, The Journal of antimicrobial chemotherapy.

Virological failure of patients on maraviroc-based antiretroviral therapy.

C. Delaugerre, J. Izopet, P. Bellecave, 2015, The Journal of antimicrobial chemotherapy.

Replicationd Patients with Ongoing HIV-1 Dynamics and Coreceptor Usage in

V. Calvez, P. Harrigan, H. Fleury, 2014 .

Replication Maraviroc-Treated Patients with Ongoing HIV-1 Dynamics and Coreceptor Usage in

V. Calvez, P. Harrigan, H. Fleury, 2013 .

HIV-1 Dynamics and Coreceptor Usage in Maraviroc-Treated Patients with Ongoing Replication

V. Calvez, P. Harrigan, B. Masquelier, 2012, Antimicrobial Agents and Chemotherapy.

Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article

G. Zalcman, D. Descamps, C. Audigier-Valette, 2021, European Journal of Cancer.

Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays

C. Charpentier, D. Descamps, N. Fidouh, 2022, Journal of Infection.

Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19

D. Annane, R. Favory, J. Pawlotsky, 2022, Nature Communications.

SARS-CoV-2 Genomic Characteristics and Clinical Impact of SARS-CoV-2 Viral Diversity in Critically Ill COVID-19 Patients: A Prospective Multicenter Cohort Study

J. Pawlotsky, L. Landraud, É. Azoulay, 2022, Viruses.

Rare Selection of the K65R Mutation in Antiretroviral-Naive Patients Failing a First-Line Abacavir/Lamivudine-Containing Haart Regimen

F. Brun-Vézinet, D. Descamps, M. Ait-Khaled, 2006, Antiviral therapy.

In vitro Phenotypic Susceptibility to Nucleoside Reverse Transcriptase Inhibitors of HIV-2 Isolates with the Q151M Mutation in the Reverse Transcriptase Gene

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2005, Antiviral therapy.

Differential activation of human neutrophils by SARS-CoV-2 variants of concern

C. Charpentier, O. Delelis, D. Descamps, 2022, Frontiers in Immunology.

Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021

C. Charpentier, S. Cauchemez, J. Pawlotsky, 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study

C. Charpentier, Y. Yazdanpanah, D. Costagliola, 2022, BMC Infectious Diseases.

Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2008, AIDS.

Pharmacokinetics of Dolutegravir in a Premature Neonate after HIV Treatment Intensification during Pregnancy

C. Charpentier, A. Desnoyer, M. Lê, 2015, Antimicrobial Agents and Chemotherapy.

Reply to Yan and Muller, “Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir’s Nephrotoxicity”

J. Timsit, H. Mal, M. Lê, 2020, Antimicrobial Agents and Chemotherapy.

Long term SARS-CoV-2 infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection

Y. Yazdanpanah, J. Lucet, F. Lescure, 2021, The Journal of infectious diseases.

Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses

E. Vicaut, C. Charpentier, G. Zalcman, 2021, medRxiv.

Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study

Y. Yazdanpanah, F. Lescure, D. Descamps, 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Associations fixes « tout en un » d’antirétroviraux en mono-prise quotidienne : mise au point pharmacologique

D. Descamps, G. Peytavin, V. Joly, 2014 .

National survey of the prevalence and conditions of selection of HIV‐1 reverse transcriptase K70E mutation

V. Calvez, C. Delaugerre, S. Yerly, 2008, Journal of medical virology.

HPV 16 in squamous cell carcinoma of 19th century tonsils.

C. Charpentier, S. Albert, D. Descamps, 2016, The Lancet Oncology.

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.

C. Charpentier, P. Harrigan, C. Katlama, 2015, The Journal of antimicrobial chemotherapy.

Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces

Tatiana F. Vieira, Henrique S. Fernandes, C. Charpentier, 2022, Antimicrobial agents and chemotherapy.

Severe Reinfection With South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant 501Y.V2

F. Uhel, D. Descamps, J. Ricard, 2021, Clinical Infectious Diseases.

Disparities in HIV‐1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations

V. Calvez, C. Charpentier, C. Katlama, 2017, HIV medicine.

A placebo-controlled clinical phase I trial with combined anti-HIV-1 and anti-interferon-alpha immunization.

P. Lebon, D. Descamps, M. Gougeon, 1997, AIDS.

SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors.

Y. Yazdanpanah, P. Morel, F. Rey, 2020, medRxiv.

Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study

E. Vicaut, M. Humbert, J. Timsit, 2020, PloS one.

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

Y. Yazdanpanah, P. Morel, F. Rey, 2020, Science Translational Medicine.

Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome

D. Descamps, B. Veber, B. Crickx, 1997, The British journal of dermatology.

Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis

Y. Yazdanpanah, C. Bonnal, M. Lê, 2018, The Journal of antimicrobial chemotherapy.

Temporal dynamics of RSV shedding and genetic diversity in adults during the COVID-19 pandemic in a French hospital, early 2021

D. Descamps, C. Tcherakian, É. Catherinot, 2022, Virus Research.

Agreement of respiratory viruses' detection between nasopharyngeal swab and bronchoalveolar lavage in adults admitted for pneumonia: a retrospective study

Y. Yazdanpanah, J. Timsit, J. Lucet, 2023, Clinical Microbiology and Infection.

Viral epidemiology and SARS‐CoV‐2 co‐infections with other respiratory viruses during the first COVID‐19 wave in Paris, France

J. Timsit, J. Lucet, E. Casalino, 2021, Influenza and other respiratory viruses.

Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection

Gilles Collin, Jean-François Timsit, Yazdan Yazdanpanah, 2020, Journal of Clinical Microbiology.

HSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients

J. Timsit, L. Bouadma, S. Ruckly, 2021, Critical Care.

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.

V. Calvez, C. Charpentier, C. Delaugerre, 2015, The Journal of antimicrobial chemotherapy.

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Xavier Duval, Jean-François Timsit, Yazdan Yazdanpanah, 2020, The Lancet Infectious Diseases.

Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors.

V. Calvez, C. Charpentier, D. Descamps, 2013, The Journal of antimicrobial chemotherapy.

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

V. Calvez, F. Brun-Vézinet, C. Delaugerre, 2000, JAMA.

Future of Antiretroviral Drugs and Evolution of HIV-1 Drug Resistance

C. Charpentier, D. Descamps, Q. Le Hingrat, 2023, Viruses.

HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells

O. Schwartz, F. Roesch, D. Descamps, 2015, Retrovirology.

Prevalence of hepatitis B among childbearing women and infant born to HBV-positive mothers in Togo

D. Descamps, D. Ekouevi, P. Coffie, 2020, BMC Infectious Diseases.

Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV‐infected patients

Y. Yazdanpanah, N. Néant, C. Solas, 2020, British journal of clinical pharmacology.

Efficacy and Tolerability of Stavudine plus Lamivudine in Treatment-Naive and Treatment-Experienced Patients with HIV-1 Infection

V. Calvez, F. Brun-Vézinet, R. Tubiana, 1998, Annals of Internal Medicine.

Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010.

V. Calvez, C. Charpentier, D. Descamps, 2013, The Journal of antimicrobial chemotherapy.

Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors

V. Calvez, F. Brun-Vézinet, B. Masquelier, 2001, Antimicrobial Agents and Chemotherapy.

Detection of Monkeypox Virus in Anorectal Swabs From Asymptomatic Men Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France

C. Charpentier, D. Descamps, L. Armand-Lefèvre, 2022, Annals of Internal Medicine.

Early Virologic Failure and Rescue Therapy of Tenofovir, Abacavir, and Lamivudine for Initial Treatment of HIV-1 Infection: TONUS Study

C. Katlama, C. Michelet, G. Peytavin, 2005, HIV clinical trials.

Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination

C. Leport, G. Peytavin, D. Descamps, 2007, AIDS.

Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine

Y. Yazdanpanah, N. Néant, C. Solas, 2018, European Journal of Clinical Pharmacology.

Quantification of Proviral Load of Human Immunodeficiency Virus Type 2 Subtypes A and B Using Real-Time PCR

F. Brun-Vézinet, D. Descamps, S. Matheron, 2001, Journal of Clinical Microbiology.

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.

C. Rouzioux, P. Frange, Laurent Tran, 2015, The Journal of antimicrobial chemotherapy.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

Jan Albert, Kirsi Liitsola, Mario Poljak, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence of hepatitis B and C among female sex workers in Togo, West Africa

C. Charpentier, D. Descamps, D. Ekouevi, 2021, PloS one.

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

F. Brun-Vézinet, C. Katlama, G. Peytavin, 2009, The Journal of antimicrobial chemotherapy.

Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients.

V. Calvez, C. Charpentier, D. Descamps, 2020, The Journal of antimicrobial chemotherapy.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

V. Calvez, C. Charpentier, C. Delaugerre, 2017, The Journal of antimicrobial chemotherapy.

New Sensitive One-Step Real-Time Duplex PCR Method for Group A and B HIV-2 RNA Load

C. Rouzioux, D. Descamps, M. Chaix, 2014, Journal of Clinical Microbiology.

The Human Immunodeficiency Virus Type 2 Vpx Protein Usurps the CUL4A-DDB1DCAF1 Ubiquitin Ligase To Overcome a Postentry Block in Macrophage Infection

A. Bergamaschi, F. Brun-Vézinet, S. Nisole, 2009, Journal of Virology.

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2008, The Journal of antimicrobial chemotherapy.

Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case‐series experience

C. Charpentier, Y. Yazdanpanah, G. Peytavin, 2016, Journal of medical virology.

HIV-1 infected patients with toxic epidermal necrolysis: an occupational risk for healthcare workers

B. Régnier, D. Descamps, P. Tattevin, 1999, The Lancet.

Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients

Philippe Flandre, Vincent Calvez, Jacques Izopet, 2008, Antimicrobial Agents and Chemotherapy.

Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients

F. Brun-Vézinet, B. Autran, G. Peytavin, 2009, AIDS.

Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case–control study

C. Charpentier, Y. Yazdanpanah, M. Lê, 2017, The Journal of antimicrobial chemotherapy.

Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with Ritonavir

C. Leport, F. Clavel, G. Peytavin, 2002, Antimicrobial Agents and Chemotherapy.

New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies.

V. Calvez, C. Katlama, J. Spano, 2020, The Journal of infectious diseases.

Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity

Y. Yazdanpanah, J. Timsit, M. Si-Tahar, 2021, Nature Immunology.

Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration

V. Calvez, C. Charpentier, O. Delelis, 2022, Journal of virology.

A new mechanism of resistance of HIV-2 to integrase inhibitors: a 5 amino-acids insertion in the integrase C-terminal domain.

C. Charpentier, R. Tubiana, F. Collin, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Reply to Das and Berkhout, “How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir”

V. Calvez, C. Charpentier, O. Delelis, 2018, mBio.

Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir

C. Charpentier, F. Brun-Vézinet, R. Tubiana, 2010, Antimicrobial Agents and Chemotherapy.

Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma

F. Brun-Vézinet, I. Williams, C. Loveday, 1996, Journal of clinical microbiology.

Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients

V. Calvez, C. Charpentier, C. Delaugerre, 2019, The Journal of antimicrobial chemotherapy.

HIV-2: A summary of present standard of care and treatment options for HIV-2 infected individuals living in Western Europe.

C. Charpentier, R. Kaiser, J. Rockstroh, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Human Immunodeficiency Virus–2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe

C. Charpentier, R. Kaiser, J. Rockstroh, 2020, Clinical Infectious Diseases.

Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.

Soo-Yon Rhee, Robert W Shafer, Philip L. Tzou, 2020, The Journal of infectious diseases.

Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads.

C. Charpentier, D. Descamps, Q. Le Hingrat, 2018, Journal of virological methods.

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)

C. Charpentier, F. Brun-Vézinet, R. Tubiana, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV-2EU-Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update.

C. Charpentier, R. Kaiser, F. Brun-Vézinet, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.

C. Charpentier, R. Tubiana, G. Peytavin, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not

C. Charpentier, O. Delelis, J. Mouscadet, 2011, Retrovirology.

In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572

C. Charpentier, F. Brun-Vézinet, R. Schinazi, 2010, AIDS.

Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors.

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1998, AIDS.

Human Immunodeficiency Virus Type 1 Subtype F Reverse Transcriptase Sequence and Drug Susceptibility

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1998, Journal of Virology.

Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1997, Journal of virology.

New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV‐1 reverse transcriptase (M184L and M184T)

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2018, Chemical biology & drug design.

Omicron SARS-CoV-2 variant: What we know and what we don’t

C. Charpentier, D. Descamps, N. Peiffer-Smadja, 2021, Anaesthesia Critical Care & Pain Medicine.

High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort

Shana M Augustin, H. Goossens, C. Charpentier, 2021, Journal of Infection.

High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in healthcare workers: results of the CoV-CONTACT prospective cohort

H. Goossens, C. Charpentier, Y. Yazdanpanah, 2020, medRxiv.

Cyclophilins and nucleoporins are required for infection mediated by capsids from circulating HIV-2 primary isolates

M. Sitbon, D. Descamps, S. Matheron, 2017, Scientific Reports.

Switch to Unusual Amino Acids at Codon 215 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene in Seroconvertors Infected with Zidovudine-Resistant Variants

F. Brun-Vézinet, S. Yerly, L. Perrin, 1998, Journal of Virology.

Detection of circulating human immunodeficiency virus type 2 in plasma by reverse transcription polymerase chain reaction.

F. Brun-Vézinet, D. Descamps, F. Simon, 1995, Research in virology.

Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network

F. Brun-Vézinet, B. Masquelier, C. Rouzioux, 2007, Antiviral therapy.

Increasing prevalence and local transmission of non-B HIV-1 subtypes in the French Antilles and French Guiana between 1995 and 2018

R. Césaire, Mathieu Nacher, D. Descamps, 2020, Virus evolution.

Analyzing Plasma HIV-1 RNA Measurements as Multiple Recurrent Events in Clinical Trials

F. Brun-Vézinet, F. Raffi, D. Descamps, 2006, HIV clinical trials.

Evaluation of SARS-CoV-2 in semen, seminal plasma, and spermatozoa pellet of COVID-19 patients in the acute stage of infection

D. Descamps, E. Ruppé, Q. Le Hingrat, 2021, PloS one.

Evidence of Sexual Transmission of Zika Virus.

Eric D'Ortenzio, Yazdan Yazdanpanah, Diane Descamps, 2016, The New England journal of medicine.

Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

V. Calvez, C. Charpentier, C. Delaugerre, 2019, The Journal of antimicrobial chemotherapy.

Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France

F. Brun-Vézinet, B. Masquelier, C. Rouzioux, 2003, AIDS.

Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)–Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58

C. Charpentier, A. Couvelard, D. Descamps, 2018, The Journal of infectious diseases.

HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man

C. Charpentier, D. Descamps, Q. Le Hingrat, 2018, Open forum infectious diseases.

Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants

V. Calvez, C. Charpentier, D. Descamps, 2018, PloS one.

Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central Africa.

F. Brun-Vézinet, D. Descamps, M. Kazanji, 2008, AIDS research and human retroviruses.

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.

Philip L. Tzou, R. Shafer, P. Harrigan, 2019, The Journal of antimicrobial chemotherapy.

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2013, The Journal of antimicrobial chemotherapy.

French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002

F. Brun-Vézinet, P. André, B. Masquelier, 2005, Journal of acquired immune deficiency syndromes.

Estimating and Comparing Reduction in HIV-1 RNA in Clinical Trials Using Methods for Interval Censored Data

D. Descamps, A. Alcais, V. Joly, 2004, Journal of acquired immune deficiency syndromes.

Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2012, The Journal of antimicrobial chemotherapy.

Plasma RNA Viral Load in Human Immunodeficiency Virus Type 2 Subtype A and Subtype B Infections

F. Brun-Vézinet, D. Robertson, D. Descamps, 2002, Journal of Clinical Microbiology.

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial

Pierre-Marie Girard, Françoise Brun-Vézinet, Diane Descamps, 2002, AIDS.

Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Jerome H. Kim, J. Ioannidis, D. Katzenstein, 2015, PLoS Medicine.

Genetic Variability of Long Terminal Repeat Region between HIV-2 Groups Impacts Transcriptional Activity

C. Charpentier, O. Schwartz, F. Collin, 2020, Journal of Virology.

Highly Sensitive Method for Amplification of Human Immunodeficiency Virus Type 2 DNA

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1998, Journal of Clinical Microbiology.

HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment.

M. Mouroux, V. Calvez, C. Rouzioux, 2000, AIDS research and human retroviruses.

Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study

P. Frange, D. Descamps, C. Dollfus, 2016, The Journal of antimicrobial chemotherapy.

Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996–2006 in France

C. Delaugerre, B. Masquelier, C. Rouzioux, 2009, AIDS.

Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Jerome H. Kim, J. Ioannidis, D. Katzenstein, 2015, PLoS medicine.

Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations

C. Charpentier, D. Descamps, 2018, Viruses.

First case of osteomyelitis due to Phialophora richardsiae in a patient with HIV infection

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1995 .

HIV-1 group O sensitivity to antiretroviral drugs.

F. Brun-Vézinet, D. Descamps, S. Saragosti, 1995, AIDS.

Plasma HIV-1 load and nosocomial transmission in Romanian children.

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1995, AIDS.

Lack of screening test sensitivity during HIV‐1 non‐subtype B seroconversions

F. Brun-Vézinet, C. Apetrei, D. Descamps, 1996, AIDS.

First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2)

C. Charpentier, D. Descamps, S. Gallien, 2021 .

Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d’Ivoire West Africa

C. Charpentier, F. Dabis, D. Descamps, 2020, PloS one.

Antiretroviral Therapy and Drug Resistance in HIV-2 Infection

F. Brun-Vézinet, D. Descamps, S. Matheron, 2014 .

Polymorphism of the Human Immunodeficiency Virus Type 2 (HIV-2) Protease Gene and Selection of Drug Resistance Mutations in HIV-2-Infected Patients Treated with Protease Inhibitors

F. Brun-Vézinet, F. Mammano, G. Peytavin, 2005, Journal of Clinical Microbiology.

Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.

V. Calvez, A. Jahn, M. Lê, 2022, The lancet. HIV.

Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates

C. Charpentier, G. Peytavin, D. Descamps, 2022, AIDS.

Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir

C. Charpentier, D. Descamps, J. Plantier, 2018, The Journal of antimicrobial chemotherapy.

Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2010, The Journal of antimicrobial chemotherapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey

C. Charpentier, D. Descamps, G. Collin, 2019 .

Gag Mutations Can Impact Virological Response to Dual-Boosted Protease Inhibitor Combinations in Antiretroviral-Naïve HIV-Infected Patients

C. Charpentier, F. Brun-Vézinet, C. Katlama, 2010, Antimicrobial Agents and Chemotherapy.

Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes

V. Calvez, C. Katlama, B. Masquelier, 2009, Antimicrobial Agents and Chemotherapy.

Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients: Week 96 Results From the ANRS 139 TRIO Trial

C. Charpentier, C. Katlama, C. Fagard, 2012, Journal of acquired immune deficiency syndromes.

Microelimination or not? The changing epidemiology of HIV-HCV coinfection in France 2012-2018.

C. Charpentier, R. Tubiana, C. Katlama, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases

V. Calvez, C. Katlama, N. Dupin, 2018, Journal of Clinical Microbiology.

A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients.

F. Brun-Vézinet, J. Izopet, C. Tamalet, 2004, The Journal of infectious diseases.

Predictive Factors and Selection of Thymidine Analogue Mutations by Nucleoside Reverse Transcriptase Inhibitors According to Initial Regimen Received

F. Brun-Vézinet, J. Izopet, C. Tamalet, 2003, Antiviral therapy.

Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V - The LAMRES Study.

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2022, Journal of global antimicrobial resistance.

Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)

C. Charpentier, F. Brun-Vézinet, C. Katlama, 2013, PloS one.

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen

C. Charpentier, F. Brun-Vézinet, C. Katlama, 2010, AIDS.

Primary infection with human herpesvirus 8 in an HIV-1-infected patient.

V. Calvez, H. Agut, N. Dupin, 2000, AIDS.

Parenteral transmission of Kaposi's sarcoma-associated herpesvirus.

V. Calvez, C. Apetrei, N. Dupin, 1998, AIDS.

Phylogenetic investigation of HCV-4d epidemic in Paris MSM HIV population reveals a still active outbreak and a strong link to the Netherlands.

C. Delaugerre, D. Descamps, Q. Le Hingrat, 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.

V. Calvez, R. Tubiana, L. Mandelbrot, 2015, Antiviral therapy.

Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients

V. Calvez, D. Kempf, M. King, 2005, Antimicrobial Agents and Chemotherapy.

Deleterious pharmacokinetic interaction between bexarotene and efavirenz.

A. Desnoyer, G. Peytavin, D. Descamps, 2010, AIDS.

Multimorbidity in Elderly Subjects according to the year of diagnosis of HIV-Infection - A Cross-Sectional DATAIDS Cohort Study.

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.

C. Charpentier, B. Masquelier, F. Raffi, 2011, The Journal of antimicrobial chemotherapy.

Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients

C. Rouzioux, J. Izopet, J. Seigneurin, 2009, AIDS.

Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).

V. Calvez, D. Podzamczer, C. Delaugerre, 2020, The Journal of antimicrobial chemotherapy.

Zidovudine Resensitization and Dual HIV-1 Resistance to Zidovudine and Lamivudine in the Delta Lamivudine Roll-Over Study

F. Brun-Vézinet, B. Masquelier, J. Izopet, 1998, Antiviral therapy.

[Parvovirus B19 infection mimicking drug-induced hypersensitivity syndrome].

D. Descamps, B. Crickx, V. Descamps, 2000, Annales de dermatologie et de venereologie.

Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss

H. Kräusslich, B. Glass, F. Clavel, 2009, PLoS pathogens.

Transmitted drug resistance in French HIV-2-infected patients

C. Charpentier, F. Brun-Vézinet, G. Peytavin, 2013, AIDS.

Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2013, AIDS.

Mutation V111I in HIV-2 Reverse Transcriptase Increases the Fitness of the Nucleoside Analogue-Resistant K65R and Q151M Viruses

P. Coveney, C. Charpentier, C. Boucher, 2014, Journal of Virology.

Prevalence of Human Papillomavirus, HIV and other sexually transmitted infections among men having sex with men in Togo: a national cross-sectional survey.

C. Charpentier, D. Descamps, D. Ekouevi, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence of HIV-1 Drug Resistance in Treated Patients: A French Nationwide Study

F. Brun-Vézinet, C. Delaugerre, S. Yerly, 2007, Journal of acquired immune deficiency syndromes.

Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey.

C. Charpentier, D. Descamps, D. Ekouevi, 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen

V. Calvez, C. Charpentier, C. Delaugerre, 2018, The Journal of antimicrobial chemotherapy.

Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study.

C. Charpentier, Y. Yazdanpanah, D. Descamps, 2016, AIDS research and human retroviruses.

Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial

V. Calvez, F. Brun-Vézinet, C. Delaugerre, 2001, Antiviral therapy.

Final analysis of the Trilège induction-maintenance trial: results at 18 months

V. Calvez, F. Raffi, G. Peytavin, 2002, AIDS.

NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.

D. Descamps, P. Yeni, V. Joly, 2002, AIDS reviews.

Low-Rate Emergence of Thymidine Analogue Mutations and Multi-Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Gene in Therapy-Naive Patients Receiving Stavudine plus Lamivudine Combination Therapy

M. Mouroux, V. Calvez, F. Brun-Vézinet, 2000, Antiviral therapy.

Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study

V. Calvez, B. Masquelier, D. Costagliola, 2001, AIDS.

Genotypic Determinants of the Virological Response to Tenofovir Disoproxil Fumarate in Nucleoside Reverse Transcriptase Inhibitor-Experienced Patients

F. Brun-Vézinet, B. Masquelier, D. Costagliola, 2003, Antiviral therapy.

Mutation V111I in HIV-2 Reverse Transcriptase Increases the Fitness of the Nucleoside Analogue-Resistant K65R and Q151M Viruses

P. Coveney, C. Charpentier, C. Boucher, 2014, Journal of Virology.

Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen

C. Charpentier, F. Brun-Vézinet, G. Peytavin, 2011, AIDS.

Positive Impact of HIV-1 gag Cleavage Site Mutations on the Virological Response to Darunavir Boosted with Ritonavir

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2011, Antimicrobial Agents and Chemotherapy.

HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.

V. Calvez, C. Charpentier, Y. Yazdanpanah, 2019, The Journal of antimicrobial chemotherapy.

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2013, AIDS.

Impact of Insertions in the HIV-1 P6 Ptapp Region on the Virological Response to Amprenavir

F. Brun-Vézinet, D. Costagliola, F. Clavel, 2004, Antiviral therapy.

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Andrew J. Oler, Eglantine Ferrand Devouge, P. Gregersen, 2023, Genome Medicine.

Impact of BNT162b2 mRNA anti-SARS-CoV-2 vaccine on interferon-alpha production by plasmacytoid dendritic cells and autoreactive T cells in patients with systemic lupus erythematosus: The COVALUS project

D. Descamps, N. Charles, J. Tchen, 2022, Journal of Autoimmunity.

Efficacy of Zidovudine Compared to Stavudine, Both in Combination with Lamivudine and Indinavir, in Human Immunodeficiency Virus-Infected Nucleoside-Experienced Patients with No Prior Exposure to Lamivudine, Stavudine, or Protease Inhibitors (Novavir Trial)

F. Brun-Vézinet, D. Descamps, C. Goujard, 2002, Antimicrobial Agents and Chemotherapy.

Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March–May 2020)

C. Charpentier, Y. Yazdanpanah, D. Descamps, 2021, Clinical Microbiology and Infection.

Evaluation of three extraction-free SARS-CoV-2 RT-PCR assays: A feasible alternative approach with low technical requirements

C. Charpentier, D. Descamps, Q. Le Hingrat, 2021, Journal of Virological Methods.

Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2

C. Delaugerre, D. Boutolleau, D. Descamps, 2020, bioRxiv.

Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.

V. Calvez, C. Charpentier, C. Katlama, 2019, The Journal of antimicrobial chemotherapy.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.

C. Delaugerre, S. Yerly, B. Masquelier, 2013, The Journal of antimicrobial chemotherapy.

High Prevalence of Antiretroviral Drug Resistance among HIV-1-Untreated Patients in Guinea-Conakry and in Niger

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2011, Antiviral therapy.

COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study

Karl Erik Müller, Jose M. Mandei, C. A. Shaw, 2021, Infection.

Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in Naive HIV-1-Infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Randomized Multicenter Trial (ANRS 130 Apollo)

C. Charpentier, C. Fagard, Y. Yazdanpanah, 2012, Antimicrobial Agents and Chemotherapy.

[HIV genetic diversity and its consequences].

F. Brun-Vézinet, D. Descamps, B. Roquebert, 2009, Pathologie-biologie.

First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022

V. Calvez, Y. Yazdanpanah, J. Pawlotsky, 2022, Infectious diseases now.

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.

V. Calvez, F. Brun-Vézinet, C. Katlama, 2009, The Journal of antimicrobial chemotherapy.

Modeling the Time Course of CD4 T-Lymphocyte Counts According to the Level of Virologic Rebound in HIV-1–Infected Patients on Highly Active Antiretroviral Therapy

D. Costagliola, D. Descamps, X. Duval, 2003, Journal of acquired immune deficiency syndromes.

Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.

V. Calvez, C. Charpentier, P. Bellecave, 2021, The Journal of antimicrobial chemotherapy.

OP-JANM190417 1..13

Philip L. Tzou, R. Shafer, P. Harrigan, 2019 .

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.

V. Calvez, C. Charpentier, B. Masquelier, 2014, The Journal of antimicrobial chemotherapy.

Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19

D. Annane, R. Favory, J. Pawlotsky, 2022, Nature Communications.

Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals

C. Charpentier, C. Delaugerre, J. Pawlotsky, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2010, Antimicrobial Agents and Chemotherapy.

Chronic use of renin‐angiotensin‐aldosterone system blockers and mortality in COVID‐19: A multicenter prospective cohort and literature review

V. Gaborieau, A. Sommet, R. Favory, 2021, Fundamental & clinical pharmacology.

Challenges and issues about organizing a hospital to respond to the COVID-19 outbreak: experience from a French reference centre

Y. Yazdanpanah, J. Timsit, L. Bouadma, 2020, Clinical Microbiology and Infection.

Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report

F. Uhel, D. Descamps, D. Roux, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)

V. Calvez, C. Charpentier, C. Delaugerre, 2018, The Journal of antimicrobial chemotherapy.

Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients

C. Charpentier, G. Carcelain, C. Delaugerre, 2021, European Journal of Clinical Microbiology & Infectious Diseases.

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Andrew J. Oler, Eglantine Ferrand Devouge, P. Gregersen, 2023, Genome Medicine.

Repeated HIV‐1 resistance genotyping external quality assessments improve virology laboratory performance

V. Calvez, F. Brun-Vézinet, C. Delaugerre, 2006, Journal of medical virology.

Management of oral antiretroviral administration in patients with swallowing disorders or with an enteral feeding tube.

Y. Yazdanpanah, B. Mourvillier, M. Wolff, 2019, Medecine et maladies infectieuses.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.

V. Calvez, C. Charpentier, M. Lê, 2020, The Journal of antimicrobial chemotherapy.

Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.

V. Calvez, C. Charpentier, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

Rhinoviruses: molecular diversity and clinical characteristics.

J. Lucet, R. Borie, D. Descamps, 2022, International Journal of Infectious Diseases.

Added value of rapid respiratory syndromic testing at point of care versus central laboratory testing: a controlled clinical trial

J. Lucet, E. Casalino, F. Lescure, 2021, The Journal of antimicrobial chemotherapy.

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

E. Vicaut, C. Charpentier, G. Zalcman, 2021, Journal of Thoracic Oncology.

Nosocomial transmission clusters and lineage diversity characterized by SARS-CoV-2 genomes from two large hospitals in Paris, France, in 2020

V. Calvez, D. Descamps, F. Blanquart, 2022, Scientific Reports.

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France

V. Calvez, C. Charpentier, J. Izopet, 2019, The Journal of antimicrobial chemotherapy.

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.

V. Calvez, C. Delaugerre, S. Yerly, 2013, International journal of antimicrobial agents.

Corrigendum to ‘detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives’

C. Charpentier, Y. Yazdanpanah, J. Timsit, 2021, Clinical Microbiology and Infection.

Triple Nucleoside Combination Zidovudine/Lamivudine/Abacavir versus Zidovudine/Lamivudine/Nelfinavir as First-Line Therapy in HIV-1-Infected Adults: A Randomized Trial

F. Brun-Vézinet, D. Descamps, S. Matheron, 2002, Antiviral therapy.

Impact of anti‐interleukin‐17 treatment on cutaneous and genital human papillomavirus infection

C. Charpentier, D. Descamps, V. Descamps, 2018, The British journal of dermatology.

New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017

V. Calvez, P. Bellecave, D. Descamps, 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Adherence to Antiretroviral Therapy and Outcomes in HIV-Infected Patients Enrolled in An Induction/Maintenance Randomized Trial

F. Brun-Vézinet, F. Raffi, G. Peytavin, 2001, Antiviral therapy.

Characterization update of HIV-1 M subtypes diversity and proposal for subtypes A and D sub-subtypes reclassification

L. Cerutti, V. Calvez, D. Descamps, 2018, Retrovirology.

SARS-CoV-2 IGM and IGG rapid serologic test for the diagnosis of COVID-19 in the emergency department

D. Boutolleau, S. Burrel, D. Descamps, 2020, Journal of Infection.

Reply to comment on 'pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'

C. Katlama, C. Fagard, Y. Yazdanpanah, 2011 .

Lamivudine and Indinavir/Ritonavir Maintenance Therapy in Highly Pretreated HIV-Infected Patients (Vista Anrs 109)

D. Costagliola, F. Clavel, G. Peytavin, 2005, Antiviral therapy.

Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2020, The Journal of antimicrobial chemotherapy.

New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification

C. Rouzioux, F. Collin, D. Descamps, 2017, Journal of Clinical Microbiology.

Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

Siti Zubaidah Othman, C. A. Shaw, Eglantine Ferrand Devouge, 2023, Kidney international reports.

Genomic diversity of mpox virus in Paris area (France) during the 2022 outbreak

C. Charpentier, Y. Yazdanpanah, D. Descamps, 2023, Journal of medical virology.

A Healthcare-Associated Infection With Monkeypox Virus of a Healthcare Worker During the 2022 Outbreak

Y. Yazdanpanah, J. Lucet, F. Lescure, 2022, Open forum infectious diseases.

Comparison of 48‐week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor‐sparing regimens: a systematic review and network meta‐analysis

M. Massetti, H. Leleu, E. Lazaro, 2018, HIV medicine.

Switch to unusual amino acid at codon 215 of the HIV-1 reverse transcriptase gene in seroconverters infected with zidovudine resistant variants

F. Brun-Vézinet, S. Yerly, L. Perrin, 1998 .

Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load.

V. Calvez, C. Charpentier, D. Descamps, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.

V. Calvez, C. Charpentier, C. Katlama, 2012, The Journal of antimicrobial chemotherapy.

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance

Jerome H. Kim, M. Poljak, R. Shafer, 2015 .

Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report

M. Lê, G. Peytavin, D. Descamps, 2020, Journal of Antimicrobial Chemotherapy.

Exploration of the effect of sequence variations located inside the binding pocket of HIV-1 and HIV-2 proteases

A. Camproux, Leslie Regad, D. Descamps, 2018, Scientific Reports.

Analysis of the HIV-2 protease’s adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet

A. Camproux, Leslie Regad, D. Descamps, 2018, Scientific Reports.

Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.

C. Charpentier, F. Brun-Vézinet, Y. Yazdanpanah, 2012, The Journal of antimicrobial chemotherapy.

Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.

V. Calvez, C. Charpentier, C. Katlama, 2015, The Journal of antimicrobial chemotherapy.

Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients

V. Calvez, C. Charpentier, C. Delaugerre, 2009, Antimicrobial Agents and Chemotherapy.

Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV‐1‐infected patients: A French nationwide study

V. Calvez, F. Brun-Vézinet, B. Masquelier, 2005, Journal of medical virology.

HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells

O. Schwartz, F. Roesch, D. Descamps, 2015, Retrovirology.

Earlier In Vitro Viral Production With SARS-CoV-2 Alpha Than With Beta, Gamma, B, or A.27 Variants

C. Charpentier, Y. Yazdanpanah, J. Timsit, 2021, Frontiers in Cellular and Infection Microbiology.

Faecal Viral Excretion and Gastrointestinal Co-Infection Do Not Explain Digestive Presentation in COVID-19 Patients

Y. Yazdanpanah, J. Timsit, C. Bonnal, 2023, Microorganisms.

Clinically relevant interpretation of genotype for resistance to abacavir

V. Calvez, F. Brun-Vézinet, B. Masquelier, 2003, AIDS.

Resistance and Virological Response Analyses in a Three Initial Treatment Strategy Trial: A Substudy of the INITIO Trial

L. Bacheler, F. Brun-Vézinet, D. Cooper, 2009, HIV clinical trials.

ANTIRETROVIRAL THERAPY IN ROMANIA : HAART ?

F. Brun-Vézinet, C. Apetrei, I. Pandrea, 2008 .

Use of Reverse Transcription-PCR-Based Assays for Quantification of HIV-1 in Dried Blood Spots Requires Specific HIV-1 RNA Isolation for Monitoring of Antiretroviral Treatment Efficiency

C. Rouzioux, D. Descamps, F. Rouet, 2014, Journal of Clinical Microbiology.

Randomized Multicenter Trial ( ANRS 130 Immunological Response : Results of a Immunosuppression Does Not Improve HIV-1-Infected Patients with Severe through Addition of Enfuvirtide in Naive Intensification of Antiretroviral Therapy

C. Charpentier, Y. Yazdanpanah, F. Raffi, 2013 .

Pharmaco‐virological algorithm to target risk of drug resistance among a population of HIV‐infected key populations in Togo

C. Charpentier, M. Lê, G. Peytavin, 2023, Journal of Medical Virology.

Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART

F. Brun-Vézinet, B. Masquelier, F. Raffi, 2006, AIDS.

High-sensitivity SARS-CoV-2 group testing by digital PCR among symptomatic patients in hospital settings

O. Gossner, A. Mallory, R. Dangla, 2021, Journal of Clinical Virology.

Characterization of HIV-2 Protease Structure by Studying Its Asymmetry at the Different Levels of Protein Description

Anne-Claude Camproux, Leslie Regad, Guillaume Ollitrault, 2018, Symmetry.

Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients

C. Charpentier, R. Tubiana, D. Descamps, 2018, The Journal of antimicrobial chemotherapy.

No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir

V. Calvez, C. Charpentier, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Predictive Value of Liver Enzymes and Inflammatory Biomarkers for the Severity of Liver Fibrosis Stage in HIV/HCV Co-Infected Patients

C. Charpentier, F. Brun-Vézinet, Y. Yazdanpanah, 2013, PloS one.

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007 – 12: impact on susceptibility to ﬁrst-line strategies

C. Rouzioux, P. Frange, Laurent Tran, 2015 .

Emerging Mutations and Associated Factors in Patients Displaying Treatment Failure on An Etravirine-Containing Regimen

V. Calvez, C. Delaugerre, B. Masquelier, 2012, Antiviral therapy.

High SARS-CoV-2 seroprevalence among street adolescents in Lomé, Togo, 2021

C. Charpentier, D. Descamps, D. Ekouevi, 2023, BMC Infectious Diseases.

Delayed HIV-1 seroconversion after antiretroviral therapy.

C. Apetrei, C. Tamalet, D. Descamps, 1998, AIDS.

Description of the L76V Resistance Protease Mutation in HIV-1 B and “Non-B” Subtypes

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2013, PloS one.

An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.

Abdel Babiker, Philippe Flandre, Peter Reiss, 1999, AIDS.

Claude Carbón, D. Descamps, P. Tattevin, 2002, Scandinavian journal of infectious diseases.

Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2023, The Journal of antimicrobial chemotherapy.

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.

S. Yerly, B. Masquelier, H. Fleury, 2013, The Journal of antimicrobial chemotherapy.

HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir.

C. Charpentier, D. Descamps, Q. Le Hingrat, 2021, The Journal of antimicrobial chemotherapy.

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Mark S. Anderson, P. Gregersen, R. Nussbaum, 2021, Science Immunology.

Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19

C. Charpentier, J. Timsit, J. Hulot, 2023, Journal of Clinical Immunology.

Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study

D. Annane, R. Favory, J. Pawlotsky, 2023, Intensive Care Medicine Experimental.

Zika virus in the female genital tract.

C. Charpentier, D. Descamps, N. Houhou-Fidouh, 2016, The Lancet. Infectious diseases.

[Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data].

D. Descamps, V. Lemée, F. Damond, 2010, Medecine et maladies infectieuses.

Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott)

C. Charpentier, C. Delaugerre, D. Descamps, 2020, Journal of Clinical Virology.

R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing Regimen

B. Masquelier, F. Raffi, B. Spire, 2003, Antimicrobial Agents and Chemotherapy.

Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen

V. Calvez, C. Charpentier, P. André, 2018, The Journal of antimicrobial chemotherapy.

Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Mutations Conferring Resistance to Nucleoside Inhibitors of Reverse Transcriptase: Comparison with Sequence Analysis

V. Calvez, C. Katlama, C. Apetrei, 1998, Journal of Clinical Microbiology.

Sequence Analysis of Reverse Transcriptase : Comparison with Conferring Resistance to Nucleoside Inhibitors Immunodeficiency Virus Type 1 Mutations Line Probe Assay for Detection of Human

V. Calvez, C. Katlama, C. Apetrei, 1998 .

Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.

B. Masquelier, H. Fleury, F. Raffi, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

C. Charpentier, C. Fagard, F. Raffi, 2013, The Journal of antimicrobial chemotherapy.

Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study.

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2020, The Journal of antimicrobial chemotherapy.

Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy

P. Massip, J. Izopet, F. Mammano, 2001, Journal of virology.

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

C. Katlama, Y. Yazdanpanah, C. Blanco-Betancourt, 2017, HIV medicine.

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV‐1 coreceptor tropism

V. Calvez, C. Charpentier, G. Carcelain, 2012, Journal of Medical Virology.

Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT’AIDS cohort

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2019, BMC Infectious Diseases.

Characteristics associated with COVID-19 or other respiratory viruses’ infections at a single-center emergency department

J. Timsit, J. Lucet, E. Casalino, 2020, PloS one.

Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).

Philippe Flandre, Françoise Brun-Vézinet, Diane Descamps, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection.

Y. Yazdanpanah, G. Peytavin, D. Descamps, 2021, The Journal of antimicrobial chemotherapy.

Was Zika introduced to Brazil by participants at the 2013 Beach Soccer World Cup held in Tahiti: A phylogeographical analysis.

C. Charpentier, D. Descamps, Q. Le Hingrat, 2019, Travel medicine and infectious disease.

HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.

V. Calvez, C. Delaugerre, S. Yerly, 2008, The Journal of antimicrobial chemotherapy.

C. Katlama, C. Fagard, Y. Yazdanpanah, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV type 1 genetic diversity and genotypic drug susceptibility in the Republic of Moldova.

D. Robertson, C. Apetrei, I. Pandrea, 2001, AIDS research and human retroviruses.

Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients

Siti Zubaidah Othman, Eyvind W. Axelsen, C. A. Shaw, 2022, Influenza and other respiratory viruses.

Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients: Week 96 Results From the ANRS 139 TRIO Trial

C. Charpentier, C. Katlama, C. Fagard, 2012, Journal of acquired immune deficiency syndromes.

C. Rouzioux, P. Frange, G. Peytavin, 2016, The lancet. HIV.

Evolution of Protease and Reverse Transcriptase Inhibitor Resistance-Associated Mutations in HIV-1-Infected Protease Inhibitor-Treated Patients with Persistent Low Viraemia

C. Leport, G. Peytavin, D. Descamps, 2005, Antiviral therapy.

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV‐1 coreceptor tropism

V. Calvez, C. Charpentier, G. Carcelain, 2012, Journal of medical virology.

Phylodynamics of SARS-CoV-2 in France, Europe, and the world in 2020

V. Calvez, C. Charpentier, D. Descamps, 2023, eLife.

Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients

B. Autran, J. Ananworanich, K. Ruxrungtham, 2009, AIDS.

Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort

J. Hasenauer, C. Charpentier, V. Gaborieau, 2023, EClinicalMedicine.